MA47522A - Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation - Google Patents

Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation

Info

Publication number
MA47522A
MA47522A MA047522A MA47522A MA47522A MA 47522 A MA47522 A MA 47522A MA 047522 A MA047522 A MA 047522A MA 47522 A MA47522 A MA 47522A MA 47522 A MA47522 A MA 47522A
Authority
MA
Morocco
Prior art keywords
vectors
compositions
methods
immunodeficiency virus
human immunodeficiency
Prior art date
Application number
MA047522A
Other languages
English (en)
Other versions
MA47522B1 (fr
Inventor
Benoit C S Callendret
Anders Krarup
Johannes Petrus Maria Langedijk
Jörn Stitz
Manen Danielle Van
Jort Vellinga
Frank Wegmann
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of MA47522A publication Critical patent/MA47522A/fr
Publication of MA47522B1 publication Critical patent/MA47522B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • C07K14/16—HIV-1 ; HIV-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
MA47522A 2015-12-15 2016-12-15 Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation MA47522B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15200138 2015-12-15
EP16194124 2016-10-17

Publications (2)

Publication Number Publication Date
MA47522A true MA47522A (fr) 2021-05-05
MA47522B1 MA47522B1 (fr) 2021-11-30

Family

ID=57737697

Family Applications (3)

Application Number Title Priority Date Filing Date
MA44059A MA44059B1 (fr) 2015-12-15 2016-12-15 Antigènes du virus de l'immunodéficience humaine, vecteurs, compositions, et leurs procédés d'utilisation
MA055825A MA55825A (fr) 2015-12-15 2016-12-15 Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation
MA47522A MA47522B1 (fr) 2015-12-15 2016-12-15 Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MA44059A MA44059B1 (fr) 2015-12-15 2016-12-15 Antigènes du virus de l'immunodéficience humaine, vecteurs, compositions, et leurs procédés d'utilisation
MA055825A MA55825A (fr) 2015-12-15 2016-12-15 Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation

Country Status (29)

Country Link
US (3) US10369214B2 (fr)
EP (3) EP3390430B1 (fr)
JP (2) JP6510149B2 (fr)
KR (1) KR20180086207A (fr)
CN (2) CN108368157B (fr)
AU (2) AU2016369326B2 (fr)
BR (1) BR112018011122A2 (fr)
CA (1) CA3008542C (fr)
CY (2) CY1122705T1 (fr)
DK (2) DK3584252T3 (fr)
EA (1) EA038974B1 (fr)
ES (2) ES2753854T3 (fr)
HR (2) HRP20211566T1 (fr)
HU (2) HUE045993T2 (fr)
IL (1) IL259942B2 (fr)
LT (2) LT3390430T (fr)
MA (3) MA44059B1 (fr)
MD (2) MD3390430T2 (fr)
ME (1) ME03545B (fr)
MX (2) MX2018007198A (fr)
PH (1) PH12018501047A1 (fr)
PL (2) PL3390430T3 (fr)
PT (1) PT3390430T (fr)
RS (2) RS62360B1 (fr)
SG (2) SG11201804411TA (fr)
SI (2) SI3390430T1 (fr)
TW (2) TWI792091B (fr)
WO (1) WO2017102929A1 (fr)
ZA (1) ZA201803978B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015320574B2 (en) 2014-09-26 2018-12-06 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for inducing protective immunity against Human Immunodeficiency Virus infection
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
EP3031923A1 (fr) * 2014-12-11 2016-06-15 Institut Pasteur Composition immunogène contre l'encéphalite japonaise à base de vecteurs lentiviraux
HUE045993T2 (hu) 2015-12-15 2020-01-28 Janssen Vaccines & Prevention Bv Emberi immunhiány vírus antigének, vektorok, készítmények és alkalmazásukra szolgáló eljárások
EA201892735A1 (ru) 2016-06-16 2019-05-31 Янссен Вэксинс Энд Превеншн Б.В. Состав вакцины против hiv
JP2019526580A (ja) 2016-09-02 2019-09-19 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 抗レトロウイルス処置を受けている対象においてヒト免疫不全ウイルス感染に対する免疫応答を誘発するための方法
RS60919B1 (sr) 2016-09-15 2020-11-30 Janssen Vaccines & Prevention Bv Trimer koji stabilizuje mutacije proteina omotača hiv
BR112019026126A2 (pt) 2017-06-15 2020-06-30 Janssen Vaccines & Prevention B.V. vetores de poxvírus que codificam antígenos do hiv e métodos de uso dos mesmos
SG11202000112XA (en) * 2017-07-19 2020-02-27 Janssen Vaccines & Prevention Bv Trimer stabilizing hiv envelope protein mutations
US20190083620A1 (en) 2017-09-18 2019-03-21 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
KR20190057276A (ko) * 2017-11-17 2019-05-28 그리폴스 다이어그노스틱 솔루션즈 인크. 신규한 포유동물 발현 인간 면역결핍 바이러스 외피 단백질 항원
CN114269363A (zh) * 2019-04-17 2022-04-01 威斯达研究所 用于hiv疫苗应用的复制缺陷型腺病毒载体
WO2020237052A1 (fr) 2019-05-22 2020-11-26 Janssen Vaccines & Prevention B.V. Procédés pour induire une réponse immunitaire contre une infection par le virus de l'immunodéficience humaine chez des sujets suivant un traitement antirétroviral
BR112022007929A2 (pt) 2019-11-07 2022-07-12 Janssen Vaccines & Prevention Bv Purificação de proteínas
WO2021228816A1 (fr) 2020-05-12 2021-11-18 Janssen Vaccines & Prevention B.V. Administration de vecteurs adénoviraux homologues
WO2022006095A2 (fr) * 2020-06-29 2022-01-06 Duke University Enveloppes mosaïques du vih-1 pour induire des réponses d'adcc
WO2022084333A1 (fr) 2020-10-20 2022-04-28 Janssen Vaccines & Prevention B.V. Régimes de vaccin contre le vih
AR124937A1 (es) 2021-02-23 2023-05-24 Janssen Vaccines & Prevention Bv Mutación estabilizante de trímeros de proteínas de la envoltura del vih
WO2023242155A1 (fr) 2022-06-14 2023-12-21 Janssen Vaccines & Prevention B.V. Compositions et procédés pour le diagnostic d'une infection par le vih

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
CA1341245C (fr) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Virus recombinant de la vaccine derive du virus modifie ankara
US5298416A (en) 1989-01-18 1994-03-29 British Technology Group Ltd. Attenuated polioviruses
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
WO1998010087A1 (fr) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Vecteurs d'adenovirus de chimpanze
US5761893A (en) 1996-10-22 1998-06-09 Lofquist Welding, Inc. Crop saving attachment for the snouts of combines
PT1550722E (pt) 1999-05-17 2007-09-25 Crucell Holland Bv ''adenovírus humano recombinante do serótipo 35''
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6710173B1 (en) 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
EP1214333A4 (fr) 1999-09-17 2005-01-19 Dana Farber Cancer Inst Inc Trimeres stabilises solubles de glycoproteines
ES2256323T5 (es) 2000-11-23 2016-11-21 Bavarian Nordic A/S Variante del virus Vaccinia Ankara Modificado
EP2280074A3 (fr) * 2001-07-05 2011-06-22 Novartis Vaccines and Diagnostics, Inc. Polynucleotides codant pour des polypeptides antigeniques du vih de sous-type b et/ou de sous-type c, polypeptides et leurs utilisations
CA2785699A1 (fr) * 2001-07-05 2003-01-16 Novartis Vaccines And Diagnostics, Inc. Polynucleotides codant des polypeptides de type c du vih antigeniques, polypeptides et leurs utilisations
JP4500049B2 (ja) 2001-12-04 2010-07-14 バヴァリアン・ノルディック・アクティーゼルスカブ フラビウイルスｎｓ１サブユニットワクチン
CN100374574C (zh) 2002-04-25 2008-03-12 克鲁塞尔荷兰公司 稳定的腺病毒载体及其增殖方法
MXPA04008891A (es) 2002-04-25 2004-11-26 Crucell Holland Bv Medios y metodos para la produccion de vectores de adenovirus.
AU2003291402A1 (en) 2002-11-07 2004-06-03 Beth Israel Deaconess Medical Center MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE
EP1578766B1 (fr) 2002-12-03 2013-02-13 University of Massachusetts Vaccins polyvalents a adn contre la glycoproteine du hiv-1 primaire et procedes de vaccination
CA2520637A1 (fr) 2003-03-28 2004-10-14 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Mva exprimant des genes modifies enveloppe, gag et pol du vih
CA2539021A1 (fr) 2003-09-15 2005-03-31 Chiron Corporation Approches combinees pour produire des reponses immunitaires
WO2005052119A2 (fr) 2003-11-19 2005-06-09 Beth Israel Deaconess Medical Center Adjuvants de la reponse immunitaire
EP3269390B1 (fr) 2004-01-23 2021-02-17 MSD Italia S.r.l. Transporteurs de vaccin adénovirus de chimpanzé
JP2007532656A (ja) * 2004-04-12 2007-11-15 アメリカ合衆国 アデノウイルスベクターを用いて免疫応答を誘導するための方法
WO2006002079A2 (fr) 2004-06-15 2006-01-05 Progenics Pharmaceuticals, Inc. Anticorps de neutralisation du vih-1 elicites par un complexe trimerique de glycoproteines d'enveloppe du vih-1
CN101277971A (zh) 2004-07-16 2008-10-01 美国政府健康及人类服务部 含cmv/r-核酸构建体的抗aids疫苗
CA2578403C (fr) * 2004-08-27 2016-04-05 Bernard Moss Virus mva recombinant exprimant des genes env, gag et pol du vih modifies par une variante a/g, une variante b et une variante c
EA010433B1 (ru) 2004-10-13 2008-08-29 Круселл Холланд Б.В. Усовершенствованные аденовирусные векторы и их применение
CN101588813A (zh) * 2005-04-12 2009-11-25 杜克大学 诱导人类免疫缺陷病毒的中和抗体的方法
US20100221241A1 (en) 2005-07-06 2010-09-02 University Of Maryland Biotechnology Institute Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites
CN101969996A (zh) 2005-08-23 2011-02-09 加利福尼亚大学董事会 多价疫苗
WO2007104792A2 (fr) 2006-03-16 2007-09-20 Crucell Holland B.V. Adénovirus recombinés basés sur les sérotypes 26 et 48 et utilisation de ceux-ci
WO2007149491A2 (fr) 2006-06-19 2007-12-27 Progenics Pharmaceuticals, Inc. Protéines env vih trimériques solubles stabilisées et leurs utilisations
EP2073840A4 (fr) 2006-10-23 2010-10-27 Progenics Pharm Inc Polypeptides d'enveloppe gp140 modifiés en provenance d'isolats du vih-1, compositions, complexes trimériques et utilisations de ceux-ci
WO2008140579A2 (fr) 2006-11-17 2008-11-20 New York University Induction d'anticorps neutralisants largement réactifs par la concentration de la réponse immunitaire sur les épitopes v3 de l'enveloppe gp120 du vih-1
EP2998316B1 (fr) 2007-03-02 2019-06-12 GlaxoSmithKline Biologicals S.A. Nouveau procédé et nouvelles compositions
LT2340038T (lt) 2008-10-10 2018-04-10 Children`S Medical Center Corporation Biocheminiu požiūriu stabilizuota živ-1 env trimero vakcina
AP3719A (en) * 2008-11-18 2016-06-30 Beth Israel Hospital Antiviral vaccines with improved cellular immunogenicity
WO2010085984A1 (fr) 2009-02-02 2010-08-05 Okairos Ag Séquences d'acide nucléique et d'acides aminés d'adénovirus simiens, vecteurs les contenant et leurs utilisations
JP5882741B2 (ja) 2009-02-02 2016-03-09 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サルアデノウイルスの核酸配列及びアミノ酸配列、それを含有するベクター、並びにその使用
WO2010096561A1 (fr) 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Protéines gag du vih/vis de synthèse et leurs utilisations
CN102711794B (zh) 2010-01-04 2015-11-25 Kj生物科学有限公司 用于疫苗和诊断学的Dps融合蛋白
DK2529010T3 (en) 2010-01-28 2017-07-24 Bavarian Nordic As MUTANTS OF VACCINIAVIRUS CONTAINING THE MAIN GENOMIC DELETIONS OF VAT
EP3178489B1 (fr) 2010-08-31 2019-11-27 Theraclone Science, Int. Anticorps de neutralisation du virus de l'immunodéficience humaine (vih)
WO2012082918A1 (fr) 2010-12-14 2012-06-21 The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Vaccins contre filovirus d'adénovirus de sérotype 26 et sérotype 35
EP2701736A1 (fr) * 2011-04-25 2014-03-05 Advanced Bioscience Laboratories, Inc. Protéines tronquées d'enveloppe (env) du vih, procédés et compositions associés à celles-ci
US20140348791A1 (en) 2011-09-09 2014-11-27 Beth Israel Deaconess Medical Center, Inc. Modified adenoviral vectors and methods of treatment using same
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
WO2013040766A1 (fr) * 2011-09-21 2013-03-28 中国疾病预防控制中心性病艾滋病预防控制中心 Procédé et vaccin pouvant induire une réponse immunitaire à large spectre contre le vih
WO2013055908A1 (fr) 2011-10-12 2013-04-18 The Scripps Research Institute Mini boucle v3 de gp120 du vih-1 et ses utilisations
US9683268B2 (en) 2012-09-19 2017-06-20 Beth Israel Deaconess Viruses associated with immunodeficiency and enteropathy and methods using same
JP2015536147A (ja) 2012-11-16 2015-12-21 ベス イスラエル デアコネス メディカル センター インコーポレイテッド 組換えアデノウイルスおよびその使用
US9932370B2 (en) 2013-01-07 2018-04-03 Beth Israel Deaconess Medical Center, Inc. Stabilized mosaic human immunodeficiency virus type 1 (HIV-1) GP140 envelope (ENV) trimers
US10248758B2 (en) 2013-02-07 2019-04-02 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
US9624510B2 (en) * 2013-03-01 2017-04-18 The Wistar Institute Adenoviral vectors comprising partial deletions of E3
US10376583B2 (en) 2013-09-30 2019-08-13 Beth Israel Deaconess Medical Center, Inc. Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator
EP3052518B1 (fr) * 2013-10-04 2020-01-08 Beth Israel Deaconess Medical Center, Inc. Vaccins de trimères d'enveloppe (env) de clade c du virus de l'immunodéficience humaine (vih) stabilisés et procédés d'utilisation de ceux-ci
CA2941116A1 (fr) * 2014-02-28 2015-09-03 Janssen Vaccines & Prevention B.V. Vecteurs adenoviaux recombines se repliquant, compositions et procedes pour les utiliser
US10400015B2 (en) 2014-09-04 2019-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant HIV-1 envelope proteins and their use
AU2015320574B2 (en) 2014-09-26 2018-12-06 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for inducing protective immunity against Human Immunodeficiency Virus infection
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
WO2016146844A1 (fr) * 2015-03-18 2016-09-22 Janssen Vaccines & Prevention B.V. Dosages pour systèmes d'expression de recombinaison
HUE045993T2 (hu) 2015-12-15 2020-01-28 Janssen Vaccines & Prevention Bv Emberi immunhiány vírus antigének, vektorok, készítmények és alkalmazásukra szolgáló eljárások
EA201892735A1 (ru) 2016-06-16 2019-05-31 Янссен Вэксинс Энд Превеншн Б.В. Состав вакцины против hiv
JP2019526580A (ja) 2016-09-02 2019-09-19 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 抗レトロウイルス処置を受けている対象においてヒト免疫不全ウイルス感染に対する免疫応答を誘発するための方法
RS60919B1 (sr) 2016-09-15 2020-11-30 Janssen Vaccines & Prevention Bv Trimer koji stabilizuje mutacije proteina omotača hiv
DE102018124348A1 (de) 2018-10-02 2020-04-02 Haver & Boecker Ohg Füllkasten und Verfahren zum Füllen von Gebinden

Also Published As

Publication number Publication date
HUE055916T2 (hu) 2021-12-28
US20210220468A1 (en) 2021-07-22
CN108368157B (zh) 2022-04-15
PT3390430T (pt) 2019-11-20
US10973907B2 (en) 2021-04-13
TWI792091B (zh) 2023-02-11
MA47522B1 (fr) 2021-11-30
EA201891415A1 (ru) 2018-11-30
HRP20191902T1 (hr) 2020-01-24
KR20180086207A (ko) 2018-07-30
LT3584252T (lt) 2021-09-27
MD3584252T2 (ro) 2022-01-31
BR112018011122A2 (pt) 2018-11-21
EP3584252B1 (fr) 2021-08-25
CN114686495A (zh) 2022-07-01
RS59447B1 (sr) 2019-11-29
EA201891415A8 (ru) 2019-10-31
ES2898271T3 (es) 2022-03-04
SG10202109457RA (en) 2021-10-28
DK3390430T3 (da) 2019-11-18
CN108368157A (zh) 2018-08-03
CA3008542C (fr) 2020-06-02
MX2018007198A (es) 2018-08-01
PL3390430T3 (pl) 2020-03-31
IL259942B (en) 2022-12-01
PH12018501047A1 (en) 2018-12-17
SI3390430T1 (sl) 2019-12-31
ME03545B (fr) 2020-07-20
CA3008542A1 (fr) 2017-06-22
US10369214B2 (en) 2019-08-06
CY1125387T1 (el) 2023-03-24
TW202106701A (zh) 2021-02-16
EP3584252A1 (fr) 2019-12-25
EP3390430A1 (fr) 2018-10-24
EA038974B1 (ru) 2021-11-17
HUE045993T2 (hu) 2020-01-28
MX2021006931A (es) 2021-07-07
JP2019146574A (ja) 2019-09-05
US11896663B2 (en) 2024-02-13
ZA201803978B (en) 2021-05-26
IL259942A (en) 2018-07-31
MA55825A (fr) 2022-03-09
SI3584252T1 (sl) 2021-11-30
JP6959289B2 (ja) 2021-11-02
PL3584252T3 (pl) 2022-01-10
WO2017102929A1 (fr) 2017-06-22
AU2019203468A1 (en) 2019-06-06
JP6510149B2 (ja) 2019-05-08
JP2019505188A (ja) 2019-02-28
CY1122705T1 (el) 2021-03-12
ES2753854T3 (es) 2020-04-14
MD3390430T2 (ro) 2019-12-31
AU2016369326A1 (en) 2018-06-07
EP3964569A1 (fr) 2022-03-09
RS62360B1 (sr) 2021-10-29
HRP20211566T1 (hr) 2022-03-04
DK3584252T3 (da) 2021-11-15
MA44059B1 (fr) 2019-11-29
EP3390430B1 (fr) 2019-08-28
MA44059A (fr) 2018-10-24
IL259942B2 (en) 2023-04-01
US20190321462A1 (en) 2019-10-24
TWI707039B (zh) 2020-10-11
AU2016369326B2 (en) 2019-02-21
US20170165355A1 (en) 2017-06-15
LT3390430T (lt) 2019-11-25
TW201734210A (zh) 2017-10-01
SG11201804411TA (en) 2018-06-28
AU2019203468B2 (en) 2020-05-21

Similar Documents

Publication Publication Date Title
MA47522A (fr) Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation
MA44740A (fr) Variantes de capsides de virus adéno-associé et leurs procédés d'utilisation
MA44077A (fr) Anticorps neutralisants le virus de l'immunodéficience humaine
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA44524A (fr) Néoantigènes et leurs procédés d'utilisation
MA42971A (fr) Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
MA43389A (fr) Anticorps anti-ox40 et leurs procédés d'utilisation
MA46529A (fr) Anticorps anti-lag-3 et leurs procédés d'utilisation
MA43658A (fr) Anticorps anti-ror1, anticorps bispécifiques ror1 x cd3, et leurs procédés d'utilisation
MA50949A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
MA42446A (fr) Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation
MA44081A (fr) Anticorps anti-c5 et leurs procédés d'utilisation
MA55097A (fr) Oxystérols et leurs procédés d'utilisation
MA47849A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA46566A (fr) Oxystérols et leurs procédés d'utilisation
MA41558A (fr) Compositions d'allergènes mélangés et leurs procédés d'utilisation
MA51552A (fr) Anticorps anti-ox40 et procédés d'utilisation
MA42409A (fr) Oxystérols et leurs procédés d'utilisation
MA54851A (fr) Oxystérols et leurs procédés d'utilisation
MA46565A (fr) Oxystérols et leurs procédés d'utilisation
MA46586A (fr) Compositions de terlipressine et leurs procédés d'utilisation
MA50403A (fr) Promédicaments de dantrolène et leurs procédés d'utilisation
MA45982A (fr) Compositions de neurostéroïdes et leurs procédés d'utilisation
MA46436A (fr) Compositions comprenant de la relaxine et leurs méthodes d'utilisation